Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
-
Shares outstanding
-
6,111,111
-
Total 13F shares
-
3,955,560
-
Share change
-
+98,356
-
Total reported value
-
$3,086,219
-
Put/Call ratio
-
0.65%
-
Price per share
-
$0.78
-
Number of holders
-
24
-
Value change
-
+$84,665
-
Number of buys
-
12
-
Number of sells
-
6
Institutional Holders of Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO) as of Q1 2024
As of 31 Mar 2024,
Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,955,560 shares.
The largest 10 holders included
Novo Holdings A/S, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock Inc., STATE STREET CORP, BANK OF AMERICA CORP /DE/, and JANE STREET GROUP, LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.